β-Elemene Enhances the Sensitivity of Osteosarcoma Cells to Doxorubicin via Downregulation of Peroxiredoxin-1

References

• Sangle NA, Layfield LJ. Telangiectatic osteosarcoma. Arch Pathol Lab Med. 2012;136(5):572–576. doi:10.5858/arpa.2011-0204-RS
   PubMed Web of Science ®Google Scholar
• Sun K, Gong C, Peng H, et al. High CCL5 expression is associated with osteosarcoma metastasis and poor prognosis of patients with osteosarcoma. Mol Med Rep. 2017;16(5):6953–6957. doi:10.3892/mmr.2017.7458
   PubMed Web of Science ®Google Scholar
• Chen J, Hu Y, Zhang L, et al. Alginate oligosaccharide DP5 exhibits antitumor effects in osteosarcoma patients following surgery. Front Pharmacol. 2017;8:623. doi:10.3389/fphar.2017.00623
   PubMed Web of Science ®Google Scholar
• Fu D, Lu C, Qu X, et al. LncRNA TTN-AS1 regulates osteosarcoma cell apoptosis and drug resistance via the miR-134-5p/MBTD1 axis. Aging (Albany NY). 2019;11(19):8374–8385. doi:10.18632/aging.102325
   PubMedGoogle Scholar
• Sun R, Muheremu A, Hu Y. miRNA-30c can be used as a target in the diagnosis and treatment of osteosarcoma. Onco Targets Ther. 2018;11:9091–9099. doi:10.2147/OTT.S181177
   PubMed Web of Science ®Google Scholar
• Wang L, Yang L, Lu Y, et al. Osthole induces cell cycle arrest and inhibits migration and invasion via PTEN/Akt pathways in osteosarcoma. Cell Physiol Biochem. 2016;38(6):2173–2182. doi:10.1159/000445573
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Wan Y, Xu L, Zhuo N, et al. The clinical significance of neoadjuvant chemotherapy in improving the drug resistance of osteosarcoma. Minerva Med. 2017;108(5):479–481. doi:10.23736/S0026-4806.17.05122-9
   PubMed Web of Science ®Google Scholar
• Yu L, Meng M, Bao Y, et al. miR-1301/TRIAP1 axis participates in epirubicin-mediated anti-proliferation and pro-apoptosis in osteosarcoma. Yonsei Med J. 2019;60(9):832–841. doi:10.3349/ymj.2019.60.9.832
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhang Y, Li R, et al. The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis. J Orthop Surg Res. 2020;15(1):51. doi:10.1186/s13018-020-1576-0
   PubMed Web of Science ®Google Scholar
• Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 2014;10(4):853–858. doi:10.4103/0973-1482.139267
   PubMed Web of Science ®Google Scholar
• Li Y, Hou H, Zhang P, Zhang Z. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy. Drug Deliv. 2020;27(1):1044–1053. doi:10.1080/10717544.2020.1785049
   PubMed Web of Science ®Google Scholar
• Cao C, Wang Q, Liu Y. Lung cancer combination therapy: doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers. Drug Des Devel Ther. 2019;13:1087–1098. doi:10.2147/DDDT.S198003
   PubMed Web of Science ®Google Scholar
• Chen P, Li X, Zhang R, et al. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation. Theranostics. 2020;10(11):5107–5119. doi:10.7150/thno.44705
   PubMed Web of Science ®Google Scholar
• Liang D, Yang M, Guo B, et al. HIF-1α induced by β-elemene protects human osteosarcoma cells from undergoing apoptosis. J Cancer Res Clin Oncol. 2012;138(11):1865–1877. doi:10.1007/s00432-012-1256-5
   PubMed Web of Science ®Google Scholar
• Tang CY, Zhu LX, Yu JD, et al. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism. Eur J Pharm Sci. 2018;120:20–29. doi:10.1016/j.ejps.2018.04.037
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. doi:10.1016/0065-2571(84)90007-4
   PubMedGoogle Scholar
• He T, Banach-Latapy A, Vernis L, et al. Peroxiredoxin 1 knockdown potentiates β-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals. Carcinogenesis. 2013;34(4):760–769. doi:10.1093/carcin/bgs389
   PubMed Web of Science ®Google Scholar
• Chen C, Lu L, Yan S, et al. Autophagy and doxorubicin resistance in cancer. Anticancer Drugs. 2018;29(1):1–9. doi:10.1097/CAD.0000000000000572
   PubMed Web of Science ®Google Scholar
• Al-Malky HS, Al Harthi SE, Osman AM. Major obstacles to doxorubicin therapy: cardiotoxicity and drug resistance. J Oncol Pharm Pract. 2020;26(2):434–444. doi:10.1177/1078155219877931
   PubMed Web of Science ®Google Scholar
• Lorusso D, Sabatucci I, Maltese G, et al. Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis. Tumori. 2019;105(4):282–287. doi:10.1177/0300891619839308
   PubMed Web of Science ®Google Scholar
• Gazzano E, Buondonno I, Marengo A, et al. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts. Cancer Lett. 2019;456:29–39. doi:10.1016/j.canlet.2019.04.029
   PubMed Web of Science ®Google Scholar
• Ma W, Yang L, Liu H, et al. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma. Biochem Biophys Res Commun. 2020;521(1):204–211. doi:10.1016/j.bbrc.2019.10.108
   PubMed Web of Science ®Google Scholar
• Buondonno I, Gazzano E, Tavanti E, et al. Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma. Cell Mol Life Sci. 2019;76(3):609–625. doi:10.1007/s00018-018-2967-9
   PubMed Web of Science ®Google Scholar
• Fu Z, Ma K, Dong B, et al. The synergistic antitumor effect of huaier combined with 5-florouracil in human cholangiocarcinoma cells. BMC Complement Altern Med. 2019;19(1):203. doi:10.1186/s12906-019-2614-5
   PubMed Web of Science ®Google Scholar
• Guo W, Tan HY, Chen F, Wang N, Feng Y. Targeting cancer metabolism to resensitize chemotherapy: potential development of cancer chemosensitizers from traditional Chinese medicines. Cancers (Basel. 2020;12(2). doi:10.3390/cancers12020404
   Web of Science ®Google Scholar
• Li QQ, Lee RX, Liang H, et al. β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK. Int J Oncol. 2013;43(3):721–728. doi:10.3892/ijo.2013.1996
   PubMed Web of Science ®Google Scholar
• Zhu TZ, Li XM, Luo LH, et al. β-elemene inhibits stemness, promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells. Int J Oncol. 2014;45(2):699–709. doi:10.3892/ijo.2014.2448
   PubMed Web of Science ®Google Scholar
• Li QQ, Wang G, Huang F, et al. Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of β-elemene and its synthetic analogs. Med Oncol. 2013;30(1):488. doi:10.1007/s12032-013-0488-9
   PubMed Web of Science ®Google Scholar
• Zhan M, Wang H, Xu SW, et al. Variants in oxidative stress-related genes affect the chemosensitivity through Nrf2-mediated signaling pathway in biliary tract cancer. EBioMedicine. 2019;48:143–160. doi:10.1016/j.ebiom.2019.08.037
   PubMed Web of Science ®Google Scholar
• Pires BRB, Panis C, Alves VD, et al. Label-free proteomics revealed oxidative stress and inflammation as factors that enhance chemoresistance in luminal breast cancer. Oxid Med Cell Longev. 2019;2019:5357649. doi:10.1155/2019/5357649
   PubMed Web of Science ®Google Scholar
• Marinello PC, Panis C, Silva TNX, et al. Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes. Sci Rep. 2019;9(1):5864. doi:10.1038/s41598-019-42357-w
   PubMed Web of Science ®Google Scholar
• Sun Y, Xu H, Chen X, Li X, Luo B. Inhibition of mitochondrial respiration overcomes hepatocellular carcinoma chemoresistance. Biochem Biophys Res Commun. 2019;508(2):626–632. doi:10.1016/j.bbrc.2018.11.182
   PubMed Web of Science ®Google Scholar
• Cao WQ, Li Y, Hou YJ, et al. Enhanced anticancer efficiency of doxorubicin against human glioma by natural borneol through triggering ROS-mediated signal. Biomed Pharmacother. 2019;118:109261. doi:10.1016/j.biopha.2019.109261
   PubMed Web of Science ®Google Scholar
• Bur H, Haapasaari KM, Turpeenniemi-Hujanen T, et al. Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas. Histopathology. 2014;65(3):319–327. doi:10.1111/his.12389
   PubMed Web of Science ®Google Scholar
• Srijiwangsa P, Ponnikorn S, Na-Bangchang K. Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. BMC Pharmacol Toxicol. 2018;19(1):32. doi:10.1186/s40360-018-0223-4
   PubMedGoogle Scholar
• Zou K, Li Z, Zhang Y, et al. β-Elemene enhances radiosensitivity in non-small-cell lung cancer by inhibiting epithelial-mesenchymal transition and cancer stem cell traits via Prx-1/NF-kB/iNOS signaling pathway. Aging (Albany NY). 2020;12.
   Google Scholar
• Albini A, Bruno A, Noonan DM, Mortara L. Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: implications for immunotherapy. Front Immunol. 2018;9:527. doi:10.3389/fimmu.2018.00527
   PubMed Web of Science ®Google Scholar
• Yin Z, Li C, Wang J, Xue L. Myeloid-derived suppressor cells: roles in the tumor microenvironment and tumor radiotherapy. Int J Cancer. 2019;144(5):933–946. doi:10.1002/ijc.31744
   PubMed Web of Science ®Google Scholar